减重版司美格鲁肽在中国的适应证或有望扩大至心血管方面。2月12日，中国国家药监局药品审评中心（CDE）官网公示显示，诺和诺德申报的司美格鲁肽注射液新适应证上市申请获得受理，此次有5个受理号，注册分类为进口3.1。

　　据悉，此次官方消息并未披露具体的适应证，但根据公开资料来看，业界认为此次受理的适应证可能是用于降低已确诊心血管疾病的肥胖或超重成人的主要不良心血管事件（MACE）风险。

　　司美格鲁肽是丹麦制药企业诺和诺德旗下的明星GLP-1药物。2024年财报显示，诺和诺德中国2024年收入为185.01亿丹麦克朗，同比增长13%，其中GLP-1药物贡献72.48亿丹麦克朗，同比增长19%。

（文章来源：广州日报）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.